Vertex announces fda approvals of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), symdeko® (tezacaftor/ivacaftor and ivacaftor) and kalydeco® (ivacaftor) for use in people with cf with certain rare mutations

Boston--(business wire)-- #cf--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the u.s. food and drug administration (fda) expanded the eligibility for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (cf) ages 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene that are responsive to trikafta based on in vitro data. symdeko® (tezacaftor/ivacaftor and ivacaftor) and kalydec
VRTX Ratings Summary
VRTX Quant Ranking